Definium Therapeutics, Inc. (DFTX)
NASDAQ: DFTX · Real-Time Price · USD
17.55
-0.21 (-1.18%)
At close: Mar 5, 2026, 4:00 PM EST
17.73
+0.18 (1.03%)
After-hours: Mar 5, 2026, 7:29 PM EST
Definium Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 48.64 | 38.62 | 41.74 | 30.16 | 58.77 | |
| Research & Development | 117.67 | 65.3 | 52.12 | 36.17 | 34.79 | |
| Operating Expenses | 166.31 | 103.92 | 93.87 | 66.33 | 93.55 | |
| Operating Income | -166.31 | -103.92 | -93.87 | -66.33 | -93.55 | |
| Interest Expense | -5.48 | -2.28 | -0.92 | - | -0.36 | |
| Interest & Investment Income | 10.96 | 11.56 | 5.58 | 1.5 | - | |
| Currency Exchange Gain (Loss) | -0.13 | -0.64 | 0.16 | 0.2 | -0.09 | |
| Other Non Operating Income (Expenses) | -22.83 | -15.94 | -6.69 | 7.85 | 0.11 | |
| EBT Excluding Unusual Items | -183.79 | -111.22 | -95.73 | -56.8 | -93.89 | |
| Merger & Restructuring Charges | - | - | - | - | -0.3 | |
| Other Unusual Items | - | 2.54 | - | - | - | |
| Pretax Income | -183.79 | -108.68 | -95.73 | -56.8 | -94.19 | |
| Income Tax Expense | - | - | - | - | -1.16 | |
| Net Income | -183.79 | -108.68 | -95.73 | -56.8 | -93.04 | |
| Net Income to Common | -183.79 | -108.68 | -95.73 | -56.8 | -93.04 | |
| Shares Outstanding (Basic) | 89 | 70 | 39 | 31 | 27 | |
| Shares Outstanding (Diluted) | 89 | 70 | 39 | 31 | 27 | |
| Shares Change (YoY) | 26.78% | 79.94% | 26.90% | 12.71% | 54.25% | |
| EPS (Basic) | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 | |
| EPS (Diluted) | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 | |
| EBITDA | -166.28 | -103.89 | - | -66.32 | -93.54 | |
| D&A For EBITDA | 0.03 | 0.03 | - | 0.02 | 0.02 | |
| EBIT | -166.31 | -103.92 | -93.87 | -66.33 | -93.55 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.